Dr. Ahmed Bakillah

Dr. Ahmed Bakillah is a Research Scientist and Head of the Research & Development Section and Research Laboratories at King Abdullah International Medical Research Center (KAIMRC), Eastern Region, Saudi Arabia. His actual area of interest is diabetes and cancer. Before joining KAIMRC, he was an Assistant Professor in the Department of Medicine at SUNY Downstate Medical Center, Brooklyn, NY.  He also served as the Research Director for the Empire Clinical Research Investigator Program (ECRIP) with the primary objective of providing basic research training to future Physician-Scientists including medical fellows and junior faculty focusing on the risk factors leading from type 2 diabetes to atherosclerotic cardiovascular disease and chronic renal disease. Dr. Bakillah completed his Ph.D. at Rene Descartes University of Paris, France, and completed his postdoctoral fellowship at the Medical College of Pennsylvania, Philadelphia, PA. Dr. Bakillah worked for almost a decade at two major pharmaceutical companies (Novo Nordisk A/S, Denmark and GlaxoSmithKline, USA). He has explored the impact of lipoprotein disorders in CVD focusing on lipid-modifying drugs in T2DM, obesity, and atherosclerosis. He has also extensively investigated the role of modified lipoproteins as early biomarkers for CVD and other related metabolic diseases. Dr. Bakillah has collaborated with researchers and experts from both Academia and Industry in the CVD field.